Charles River Laboratories Intl. Inc vs Harley-Davidson Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Harley-Davidson Inc trades at $26.13 (market cap $2.64B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 4.2× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.93% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | HOG | |
|---|---|---|
Market Cap | $11.14B | $2.64B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $31.03 |
52-Week Low | $145.57 | $17.19 |
Enterprise Value | $14.00B | $3.04B |
Dividend Yield | — | 2.93% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Harley-Davidson (HOG) trades at $25.39, up 0.99% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue from $5.8B in 2022 to $4.5B in 2025 and net income dropping to $339M, though valuation ratios remain attractive with P/E of 13.16 and P/B of 0.87. Recent news highlights production returning to US facilities and Q2 2026 earnings scheduled for July 23, 2026.
The outlook is cautiously optimistic with analyst consensus at Hold (65.71%) and price target of $23.40 below current price. Key opportunities include cost cuts and US production shift, while risks involve margin pressure and competitive threats. The stock faces headwinds from recent earnings misses but maintains dividend payments and institutional interest.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →